ADC Therapeutics (ADCT) Invested Capital (2019 - 2026)

ADC Therapeutics has disclosed Invested Capital across 8 years of filings, most recently posting -$91.6 million for Q1 2026.

• Invested Capital for Q1 2026 came in at -$91.6 million, up 19.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$91.6 million (up 19.25% YoY), and the FY2025 annual result was -$61.1 million, up 21.58% from the prior year.
• Invested Capital came in at -$91.6 million for Q1 2026 at ADC Therapeutics, down from -$61.1 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $506.3 million in Q4 2022 to a low of -$113.5 million in Q1 2025.
• The 5-year median for Invested Capital is -$62.7 million (2023), against an average of -$16.3 million.
• Across the five-year window, Invested Capital surged 64.82% in 2024 and plunged 974.23% in 2025, its largest moves.
• ADC Therapeutics' Invested Capital stood at $506.3 million in 2022, then tumbled by 104.64% to -$23.5 million in 2023, then tumbled by 231.37% to -$77.9 million in 2024, then climbed by 21.58% to -$61.1 million in 2025, then plunged by 49.99% to -$91.6 million in 2026.
• The last three Invested Capital figures came in at -$91.6 million (Q1 2026), -$61.1 million (Q4 2025), and -$113.4 million (Q3 2025), per Business Quant data.